American Dreamin, one of the nation’s leading 2-year-old Quarter Horse fillies in 2024, tested positive for carmoterol following a win in a major futurity trial at Los Alamitos last November, her third positive for the banned medication in a six-week period, according to the California Horse Racing Board’s website. In late January, the racing board announced that three horses trained by Monty Arrossa, including American Dreamin, showed the presence of carmoterol in four post-race and out-of-competition tests taken in late October and early November. One of the positives was found in a post-race sample taken from American Dreamin after she won the $1,046,800 Golden State Million Futurity on Oct. 27. The recently announced positive was taken in an out-of-competition test taken after American Dreamin won a time trial on Nov. 24 for the $1.83 million Los Alamitos Two Million Futurity. American Dreamin finished fourth in the final on Dec. 15. Carmoterol is a bronchodilator not permitted to appear in post-race tests. As a class 1 medication, trainers with carmoterol positives are subject to potential lengthy suspensions and substantial fines, according to the racing board rule pertaining to medication violations. :: Subscribe to the DRF Post Time Email Newsletter: Get the news you need to play today's races!  The racing board’s rules state that horses that test positive for class 1 medications be disqualified from prize money and that purses are to be redistributed, absent the findings of mitigating circumstances. Last week, the racing board issued three complaints in cases involving Arrossa-trained horses that tested positive for carmoterol. Two complaints ordered the redistribution of all or part of two major stakes. American Dreamin earned $439,656 for winning the Golden State Million Futurity, which was ordered forfeited in the complaint. A second complaint ordered that part of the purse of the $763,000 Los Alamitos Super Derby on Nov. 10 be redistributed after second-place finisher AB Seis Corazones tested positive for carmoterol. AB Seis Corazones earned $129,710. Both American Dreamin and AB Seis Corazones raced for owners Matt and Bendi Dunn. A third complaint was filed against Arrossa, alleging violations of several racing board rules, including positive tests for unauthorized medications, having multiple violations, and that trainers are responsible for the condition of their starters. As of Wednesday, the Los Alamitos board of stewards had not issued rulings ordering the redistribution of purses involving AB Seis Corazones or American Dreamin, or scheduled a formal hearing with Arrossa. Overall, the racing board has announced that five positive tests for carmoterol were found last fall at Los Alamitos, including an out-of-competition test taken from American Dreamin on Oct. 20 after a win in the Golden State Million Futurity trials on Oct. 5. Blood Viper, who finished fourth in the Golden State Million Futurity, tested positive once, on Oct. 20 in an out-of-competition test following a time trial. Blood Viper races for the Dunns and is trained by Arrossa. Jeff Blea, California’s equine medical director, said last month that American Dreamin and Blood Viper were allowed to start in the Golden State Million Futurity because the results of the out-of-competition tests had not been finalized with a second lab before the lucrative final. Arrossa ranked fifth among the nation’s Quarter Horse trainers in 2024 with earnings of $3,817,560 and led the nation’s trainers in earnings in 2020 and 2021. In 2024, Arrossa had 70 winners from 321 starters. A native of Idaho, Arrossa has had a dominant stable at Los Alamitos for nearly a decade. Earlier this month, the New Mexico State Racing Commission announced that 12 horses that raced at the Downs at Albuquerque on Sept. 2, 2024, tested positive for carmoterol, including Hezgothelook Z, the winner of the $3 million All American Futurity. The trainers involved in those cases – Toby Keeton and Heath Taylor – were summarily suspended by New Mexico officials. Arrossa has been allowed to continue training in California until a hearing is conducted, which is California Horse Racing Board policy. :: Want to learn more about handicapping and wagering? Check out DRF's Handicapping 101 and Wagering 101 pages.